Citigroup’s Avenue Therapeutics ATXI Stock Holding History
Bought
Maintained
Sold
Other funds holding ATXI
SM
Citigroup's ATXI Position: Q1 2023 in Review
Citigroup sold out of Avenue Therapeutics (ATXI) in Q1 2023, closing a stake of 231 shares — an estimated $20.1K sold.
Citigroup first reported a position in ATXI in Q1 2020 and held it in 5 quarters. The position peaked at $20.1K in Q4 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2023.
- Citigroup reported no remaining Avenue Therapeutics position as of Q1 2023 after selling out during the quarter.
- Citigroup sold 231 Avenue Therapeutics shares in Q1 2023, an estimated $20.1K.
- Citigroup first reported a position in Avenue Therapeutics in Q1 2020 and held it in 5 quarters.
- Citigroup's Avenue Therapeutics position peaked at $20.1K in Q4 2022.
- 13 funds tracked by Wall St. Rank held Avenue Therapeutics as of Q1 2023.
Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.